This study reveals the critical role of DCLK1 in bladder cancer through single-cell sequencing, elucidating how it promotes tumor progression, drug resistance, and immune evasion by stabilizing HDAC6 and activating the Notch/PD-L1 pathway, offering new strategies for combination therapy.
Literature Overview
The article titled "DCLK1 drives malignant progression and chemoresistance of bladder cancer by deubiquitinating HDAC6," published in the journal Molecular Cancer, reviews and summarizes the oncogenic mechanisms of DCLK1 in bladder cancer. By integrating single-cell RNA sequencing with functional experiments, the study systematically analyzes the heterogeneity of the tumor microenvironment and identifies DCLK1 as a key molecule driving tumor stemness, metastasis, cisplatin resistance, and immune escape. It further reveals that DCLK1 functions by promoting the USP10-HDAC6 interaction and inhibiting HDAC6 degradation. Additionally, DCLK1 activates the Notch signaling pathway to upregulate PD-L1 expression and suppress CD8⁺ T cell activity. In vivo models demonstrate that targeting DCLK1 in combination with cisplatin and an HDAC6 inhibitor significantly enhances antitumor efficacy. This study provides a mechanistic basis and potential therapeutic strategies for overcoming chemotherapy resistance in bladder cancer.Background Knowledge
Bladder cancer is the most common malignant tumor of the urinary system, and patients with muscle-invasive or metastatic disease often have poor prognoses and are frequently ineligible for radical surgery. Cisplatin-based chemotherapy remains the first-line treatment for advanced patients, but most eventually develop resistance, leading to treatment failure. Resistance mechanisms are complex, involving tumor heterogeneity, stemness maintenance, enhanced DNA repair, and immunosuppressive microenvironments. In recent years, single-cell transcriptomic technologies have provided high-resolution tools for dissecting intratumoral heterogeneity and microenvironment interactions, facilitating the discovery of novel driver genes and therapeutic targets. DCLK1 is a microtubule-associated protein kinase highly expressed in various cancers and associated with stem-like properties, epithelial-mesenchymal transition (EMT), drug resistance, and immune regulation. HDAC6, a member of the histone deacetylase family, participates in protein stability, cytoskeletal dynamics, and immune regulation, with its abnormal stabilization linked to tumor progression. USP10 is a deubiquitinating enzyme that regulates the ubiquitination level of HDAC6. However, whether DCLK1 regulates the USP10-HDAC6 axis in bladder cancer remains unclear. Furthermore, the PD-L1/PD-1 immune checkpoint pathway is a major mechanism of tumor immune evasion, but its upstream regulatory network requires further elucidation. This study focuses on the multifaceted functions of DCLK1 in bladder cancer, exploring its role in chemotherapy resistance and immune escape, filling existing research gaps and providing a theoretical foundation for developing DCLK1-targeted combination therapies.
Research Methods and Experiments
The study employed single-cell RNA sequencing (scRNA-seq) to analyze normal, adjacent, and metastatic tumor tissues from four bladder cancer patients, systematically characterizing the cellular composition and expression programs of the tumor microenvironment. Through differential expression analysis and functional enrichment, six evolutionarily conserved expression programs in cancer cells were identified, including proliferation, metastasis, and immune evasion, with DCLK1 showing significant enrichment in metastasis-related programs. In cell lines, gene knockdown and overexpression mediated by shRNA were used to evaluate the impact of DCLK1 on cell stemness (tumor sphere formation), cisplatin sensitivity (CCK-8, Annexin V/PI), migration and invasion (Transwell), and EMT. CFSE staining, ELISA, and co-culture assays were performed to analyze how DCLK1 regulates CD8⁺ T cell proliferation, apoptosis, and cytokine secretion. Co-immunoprecipitation (Co-IP), RNA pull-down, mass spectrometry, and molecular docking were used to validate the interactions and subcellular localization among DCLK1, USP10, and HDAC6. Deubiquitination assays and in vitro ubiquitination reactions clarified the role of the DCLK1-USP10 complex in deubiquitinating HDAC6. Finally, the antitumor efficacy of targeting DCLK1 in combination with cisplatin and the HDAC6 inhibitor ACY-1215 was evaluated in nude mouse xenograft models.Key Conclusions and Perspectives
Research Significance and Prospects
This study systematically reveals the central regulatory role of DCLK1 in bladder cancer progression, functioning not only as a promoter of metastasis and stemness maintenance but also cooperatively driving chemotherapy resistance and immune escape through dual mechanisms—stabilizing HDAC6 and activating the Notch/PD-L1 pathway. This finding expands our understanding of the non-kinase functions of DCLK1, underscoring the importance of its role as a molecular scaffold in tumorigenesis.
The study provides new intervention points for overcoming cisplatin resistance. Targeting DCLK1 may simultaneously block multiple oncogenic pathways, enhance chemosensitivity, and improve the immune microenvironment. The strategy of combining DCLK1 inhibitors with cisplatin and HDAC6 inhibitors warrants further exploration and holds promise for improving treatment outcomes in advanced bladder cancer. Moreover, DCLK1 could serve as a predictive biomarker to identify patient populations likely to benefit from targeted therapies.
Conclusion
This study integrates single-cell transcriptomics with functional validation to reveal DCLK1 as a key driver of malignant progression in bladder cancer. DCLK1 not only promotes tumor stemness and metastasis but also exacerbates disease progression through dual mechanisms: first, by acting as a scaffold protein that facilitates the USP10-HDAC6 interaction, leading to deubiquitination and stabilization of HDAC6, thereby enhancing tumor cell survival and drug resistance; second, by activating the Notch signaling pathway to upregulate PD-L1 expression, suppressing CD8⁺ T cell function and mediating immune escape. Functional experiments confirm that inhibiting DCLK1 significantly enhances cisplatin sensitivity and improves antitumor efficacy in animal models when combined with other therapies. This study systematically elucidates the synergistic roles of the DCLK1-USP10-HDAC6 and Notch-PD-L1 pathways, providing new therapeutic targets and combination strategies for precision treatment of bladder cancer. The future development of DCLK1-specific inhibitors may offer a novel clinical approach to overcoming chemotherapy resistance and immune suppression.
